Oncogenic viruses

🧬 Oncogenic viruses (oncoviruses) can contribute to cancer by driving chronic inflammation 🔥, suppressing tumour suppressor pathways 🛑, promoting uncontrolled cell cycling ⚙️, and helping infected cells evade immune clearance 🥷. Globally, a meaningful minority of cancers are attributable to infections (including viruses), and a large proportion of cancers are preventable through vaccination, screening, and risk reduction 🛡️.

🧠 Core idea: how viruses push cells toward cancer

• ⚙️ Cell-cycle hijack: viral proteins can disable key “brakes” (e.g., p53/Rb pathways), so cells divide when they shouldn’t.
• 🧬 Genomic instability: repeated replication stress and impaired DNA repair increase mutation burden over time.
• 🔥 Chronic inflammation: long-term infection causes cycles of injury/repair → oxidative stress and fibrosis (classic in chronic viral hepatitis).
• 🥷 Immune evasion: viruses can reduce antigen presentation or create immunosuppressive microenvironments, letting abnormal clones persist.
• 🧩 Integration / persistence: some viruses integrate into host DNA or establish latency, creating long-lived infected cell reservoirs.

📌 Big-picture epidemiology (why it matters)

• 🌍 Infections cause a substantial fraction of cancers worldwide (higher in many low- and middle-income settings), meaning prevention can be highly effective.
• 🛡️ Many cancers are preventable overall through public health measures (vaccination, screening, tobacco control, etc.).

🦠 Major oncogenic viruses and their “classic” cancers

• 🧫 High-risk HPV (e.g., types 16/18): cervical cancer; also anal, vulvar/vaginal, penile, and many oropharyngeal cancers. :contentReference[oaicite:3]{index=3}
• 🧪 Hepatitis B virus (HBV) and 🧪 Hepatitis C virus (HCV): hepatocellular carcinoma (HCC) (risk rises particularly with cirrhosis). :contentReference[oaicite:4]{index=4}
• 💋 Epstein–Barr virus (EBV): Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, and some gastric cancers (especially in specific geographic/immune contexts). :contentReference[oaicite:5]{index=5}
• 🟣 Kaposi sarcoma-associated herpesvirus (KSHV/HHV-8): Kaposi sarcoma; some lymphoproliferative diseases (especially with immunosuppression). :contentReference[oaicite:6]{index=6}
• 🧬 HTLV-1: adult T-cell leukaemia/lymphoma (ATLL). :contentReference[oaicite:7]{index=7}
• 🟠 Merkel cell polyomavirus (MCPyV): strongly associated with Merkel cell carcinoma; it has been formally evaluated within the IARC Monographs process (Volume 139). :contentReference[oaicite:8]{index=8}

🔬 Virus-by-virus “mechanism snapshot” (high-yield)

• 🧷 HPV: persistent infection in transformation zones; viral oncoproteins (E6/E7) disable tumour suppressor checkpoints → dysplasia → carcinoma sequence (why screening & vaccination work so well).
• 🫀 HBV/HCV: repeated hepatocyte injury + regeneration in chronic hepatitis; fibrosis/cirrhosis creates a pro-oncogenic environment; antiviral treatment reduces (but may not eliminate) long-term HCC risk once cirrhosis is established.
• 🧠 EBV: latency programs in B cells/epithelium provide survival/proliferation signals; risk rises when immune surveillance is impaired (e.g., post-transplant immunosuppression).
• 🟣 KSHV (HHV-8): pro-angiogenic and pro-survival signalling → vascular tumours (Kaposi) particularly when cellular immunity is weakened.
• 🧬 HTLV-1: long latency; viral regulatory proteins drive T-cell proliferation and survival, increasing the chance of malignant transformation over time.
• 🟠 MCPyV: in the subset of Merkel cell carcinomas linked to MCPyV, viral “T-antigen” biology and tumour immune evasion are key themes (often in older or immunosuppressed patients).

🛡️ Prevention (UK clinical context)

• 💉 HPV vaccination: prevents the majority of HPV-driven cervical disease and contributes to prevention of other HPV-related cancers; still promote screening participation where applicable. :contentReference[oaicite:9]{index=9}
• 🩸 Viral hepatitis control: HBV vaccination (targeted and occupational risk groups) and HCV case-finding + treatment reduce future liver cancer burden.
• 🔎 Screening: cervical screening detects treatable pre-cancer (CIN); liver surveillance is used in selected chronic hepatitis/cirrhosis patients to detect HCC early.
• 🧼 Transmission reduction: safer sex, needle safety, blood product screening, and perinatal HBV prevention strategies.
• 🧑‍⚕️ Immunosuppression awareness: transplant recipients and people with advanced HIV are at higher risk of virus-associated malignancies → lower threshold for investigation of “atypical” lesions.

💡 Clinical pearls (exam + ward)

• 🎯 If you remember one mechanism: persistent infection + immune escape + chronic inflammation is the common road to cancer across many oncoviruses.
• 🧪 In adults with new nephrotic syndrome we talk about thrombotic risk; with oncoviruses, the parallel “high-yield risk” is persistence - brief infections rarely cause cancer.
• 🧾 Don’t overclaim causality: many viruses are common, but only a minority of infected people develop malignancy - co-factors (immune status, smoking, co-infections, genetics) matter.

📚 References

• WHO / IARC (news release, 2026). Prevention estimates and infection-attributable cancer burden.
• American Cancer Society. Known and probable human carcinogens (includes oncogenic viruses). :contentReference[oaicite:11]{index=11}
• WHO. Cervical cancer (HPV link and prevention). :contentReference[oaicite:12]{index=12}
• Karagas MR, et al. Lancet Oncology (IARC Monographs Volume 139 overview: HDV, HCMV, MCPyV). :contentReference[oaicite:13]{index=13}